ALT Q4 2023 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$353M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37,000+133.6% YoY

Gross Profit

$37,000100.0% margin

Operating Income

-$34M-90873.0% margin

Net Income

-$32M-85516.2% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

-89.8%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$211M

Total Liabilities

$17M

Stockholders' Equity

$194M

Cash & Equivalents

$135M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37,000	-$110,000	+133.6%
Gross Profit	$37,000	-$19M	+100.2%
Operating Income	-$34M	-$23M	-45.6%
Net Income	-$32M	-$22M	-46.1%